Articles From: Sapient Global Markets and OpenLink Announce Collaboration to Enhance Portfolio and Asset Optimization for Energy Market Participants to Sasol Limited: Trading Statement for the Financial Year Ended 30 June 2014


Sapient Global Markets , a division of Sapient (NASDAQ: SAPE), and a leading global provider of business technology and consulting services for the capital and commodity markets, and OpenLink, a leading provider of software for the commodity and energy industries, today announced a new collaboration around the OpenLink IRM platform.
Sign-up for Sapient Global Markets and OpenLink Announce Collaboration to Enhance Portfolio and Asset Optimization for Energy Market Participants investment picks
Sapient Global Markets , a division of Sapient (NASDAQ: SAPE), and a leading global provider of business technology and consulting services for the capital and commodity markets, today announced further enhancements to its Compliance Management and Reporting System (CMRS) to support collateral and valuation reporting.
Sign-up for Sapient Global Markets Supports EMIR Collateral and Valuation Reporting Through CMRS Enhancements investment picks
Sapient Global Markets , a division of Sapient (NASDAQ: SAPE), and a leading global provider of business technology and consulting services for the capital and commodity markets, today published a new white paper ‘Bringing Efficiency to Collateral Management’ .
Sign-up for Sapient Global Markets White Paper Examines How to Drive Greater Efficiencies Across Collateral Management Operations investment picks
Sapient (NASDAQ: SAPE) today reported the following financial results for the second quarter ended June 30, 2014: “We are very pleased with the results we’ve posted in the first half of 2014 despite the challenging economic environment,” said Sapient Chief Executive Officer and Co-Chairman Alan J.
Sign-up for Sapient Reports Second Quarter 2014 Results investment picks
Sapient (NASDAQ: SAPE) today announced that it will release results for the second quarter ended June 30, 2014 on Wednesday, August 6, 2014 after the close of regular market hours.
Sign-up for Sapient to Announce Second Quarter Financial Results on August 6 investment picks
Sapient (NASDAQ: SAPE) today announced that Alan J.
Sign-up for Sapient to Present at Citi Global Technology Conference investment picks
2014/7/16
JOHANNESBURG, South Africa, July 16, 2014 /PRNewswire/ -- Sappi today confirmed that they have concluded the sale of Sappi's Usutu Forest Products Company Limited to local Swaziland business Montigny Investments.
Sign-up for Sappi confirms purchase by Montigny Investments of Sappi's Usutu business in Swaziland investment picks
2014/6/19
Selecting the finest in printing from 1700 entries BOSTON , June 19, 2014 /PRNewswire/ -- Sappi Fine Paper North America today announced the Printer of the Year and 11 Gold Award winners of its 17th North American Printer of the Year contest.
Sign-up for Sappi Fine Paper North America Announces Printer of the Year Winners in 17th Year of Competition investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0961390001&sourceType=1 http://www.ccnmatthews.com/logos2/saputo.gif MONTREAL, QUEBEC --
Sign-up for Saputo Announces Election of Directors investment picks
2014/6/23
The specialty cheese group of Saputo Cheese USA Inc. (“Saputo Cheese”) is launching seven new specialty cheese items this June.
Sign-up for Saputo Cheese USA Inc. Launches Seven New Items, Value-Added Enhancements to Nikos® Brand at Summer Fancy Food Show investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0960920001&sourceType=1 http://www.ccnmatthews.com/logos2/saputo.gif MONTREAL, QUEBEC --
Sign-up for Saputo Inc.: Financial Results for Fiscal 2015 First Quarter Ended June 30, 2014 investment picks
SAN RAFAEL, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Sarah Cannon Research UK today announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation.
Sign-up for Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation investment picks
2014/6/20
Cambridge Bancorp and its subsidiary, Cambridge Trust Company, announced the appointment of Sarah (Sally) G.
Sign-up for Sarah G. Green Joins Board of Directors of Cambridge Trust Company investment picks
2014/8/18
Nordstrom-exclusive collection includes riding boots, pumps, and new handbags SEATTLE , Aug.
Sign-up for Sarah Jessica Parker's SJP Collection Available in Five Additional Nordstrom Stores for Fall 2014 investment picks
NEW YORK , July 14, 2014 /PRNewswire/ -- Saratoga Investment Corp.
Sign-up for Saratoga Investment Corp. Announces Fiscal First Quarter 2015 Financial Results investment picks
NEW YORK , June 24, 2014 /PRNewswire/ -- Saratoga Investment Corp.
Sign-up for Saratoga Investment Corp. to Report Fiscal First Quarter 2015 Financial Results and Hold Conference Call investment picks
Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, and Flagship Biosciences LLC, a leading tissue-based companion diagnostics firm, today announced a multi-year, multi-product partnership for the development of automated quantitative endpoint measurements in muscular dystrophy to support the advancement of Sarepta’s Duchenne muscular dystrophy (DMD) drug pipeline, including its lead candidate, eteplirsen.
Sign-up for Sarepta Enters into Partnership with Flagship Biosciences to Digitally Automate the Measurement of Dystrophin, a Key Therapeutic Efficacy Marker for Muscular Dystrophy investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that John Hodgman, a member of Sarepta’s board of directors, has been named interim chairman, effective July 30, 2014.
Sign-up for Sarepta Therapeutics Announces Appointment of John Hodgman As Interim Chairman investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three and six months ended June 30, 2014, and provided an update of recent corporate developments.
Sign-up for Sarepta Therapeutics Announces Second Quarter 2014 Financial Results and Recent Corporate Developments investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 144 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). After nearly three years of follow up, results on the 6-minute walk test (6MWT) showed a decline in walking ability at a rate slower than would be expected based on available DMD natural history data.
Sign-up for Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report second quarter 2014 financial results before the NASDAQ Global Market opens on Thursday, August 7, 2014.
Sign-up for Sarepta Therapeutics to Announce Second Quarter 2014 Financial Results and Corporate Update on August 7, 2014 investment picks
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management will present a company overview at the Canaccord 34 th Annual Growth Conference in Boston, MA on Wednesday, August 13, 2014, at 4:30 pm, ET.
Sign-up for Sarepta Therapeutics to Present Company Overview at Canaccord Annual Growth Conference investment picks
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the JMP Securities Healthcare Conference in New York, NY on Tuesday, June 24, 2014 at 3:30 p.m. Eastern Time.
Sign-up for Sarepta Therapeutics to Present Company Overview at the JMP Securities Healthcare Conference on June 24 investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in September.
Sign-up for Sarepta Therapeutics to Present Company Overview at Upcoming Conferences investment picks
2014/7/8
SAS Provides an Exploration Update for the Smoke Deep Zone at the Holloway Mine Canada NewsWire Drilling Returns: 13.07 g/t Au over 31.6m (7.43 g/t Au Cut); and 11.10 g/t Au over 8.9m (10.72 g/t Au Cut) TORONTO , July 8, 2014 /CNW/ - St Andrew Goldfields Ltd.
Sign-up for SAS Provides an Exploration Update for the Smoke Deep Zone at the Holloway Mine investment picks
2014/9/11
SAS provides update on Taylor and Hislop drill programs Canada NewsWire Drilling at Taylor returns: 12.98 g/t Au over 15.3 metres (9.79 g/t Au cut) Drilling at Hislop returns: 10.38 g/t Au over 25.0 metres (5.58 g/t Au cut) TORONTO , Sept.
Sign-up for SAS provides update on Taylor and Hislop drill programs investment picks
2014/8/13
SAS reports solid 2014 second quarter results and raises production guidance Canada NewsWire All dollar amounts are stated in Canadian dollars, unless otherwise indicated TORONTO , Aug.
Sign-up for SAS reports solid 2014 second quarter results and raises production guidance investment picks
2014/9/8
JOHANNESBURG--Sasol Ltd.
Sign-up for Sasol Annual Profit Rises investment picks
2014/9/8
JOHANNESBURG , September 8, 2014 /PRNewswire/ -- Highlights Synfuels production volumes of 7,6 million tons - highest in a decade ORYX GTL plant achieved an average utilisation rate of 97% Normalised cash fixed costs - 1,8% below SA PPI Headline earnings per share up by 14% to a record R60,16 Total dividend of R21,50 per share, up by 13% Total skills development and socioeconomic spend of R1,4 billion Business performance enhancement programme to deliver increased annual savings of at least R4 billion by 2016 Capital expenditure of R39,5 billion - 57% invested in South Africa A new era for Sasol President and Chief Executive Officer, David E.
Sign-up for Sasol Headline Earnings Per Share up by 14% to a Record R60,16 investment picks
JOHANNESBURG , August 11, 2014 /PRNewswire/ -- Sasol's headline earnings per share (HEPS) for the financial year ended 30 June 2014 is expected to increase by between 11% and 17%, and earnings per share (EPS), for the same period, is expected to increase by between 9% and 15%, compared to the prior financial year.
Sign-up for Sasol Limited: Trading Statement for the Financial Year Ended 30 June 2014 investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Sapient Global Markets and OpenLink Announce Collaboration to Enhance Portfolio and Asset Optimization for Energy Market Participants to Sasol Limited: Trading Statement for the Financial Year Ended 30 June 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices